Vascular Biogenics Ltd. [NASDAQ: VBLT] gained 29.66% on the last trading session, reaching $0.17 price per share at the time. The company report on February 23, 2023 that VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement.
Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable’s proprietary Predictive Precision Medicines Platform (“PPMP”).
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Notable’s validated PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient’s cancer treatment and predict their clinical response to the actual treatment.
Vascular Biogenics Ltd. represents 77.63 million in outstanding shares, while the company has a total market value of $12.16 million with the latest information. VBLT stock price has been found in the range of $0.1653 to $0.25.
If compared to the average trading volume of 1.56M shares, VBLT reached a trading volume of 153335545 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Vascular Biogenics Ltd. [VBLT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VBLT shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VBLT stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Vascular Biogenics Ltd. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on July 20, 2022. The new note on the price target was released on July 20, 2022, representing the official price target for Vascular Biogenics Ltd. stock. Previously, the target price had yet another raise to $5.50, while Oppenheimer analysts kept a Outperform rating on VBLT stock.
The Average True Range (ATR) for Vascular Biogenics Ltd. is set at 0.02, with the Price to Sales ratio for VBLT stock in the period of the last 12 months amounting to 13.51. The Price to Book ratio for the last quarter was 0.51, with the Price to Cash per share for the same quarter was set at 0.38.
Trading performance analysis for VBLT stock
Vascular Biogenics Ltd. [VBLT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.49. With this latest performance, VBLT shares gained by 7.20% in over the last four-week period, additionally sinking by -20.05% over the last 6 months – not to mention a drop of -87.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VBLT stock in for the last two-week period is set at 59.89, with the RSI for the last a single of trading hit 64.26, and the three-weeks RSI is set at 57.31 for Vascular Biogenics Ltd. [VBLT]. The present Moving Average for the last 50 days of trading for this stock 0.1419, while it was recorded at 0.1423 for the last single week of trading, and 0.5240 for the last 200 days.
Vascular Biogenics Ltd. [VBLT]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Vascular Biogenics Ltd. [VBLT] shares currently have an operating margin of -3905.73 and a Gross Margin at -111.07. Vascular Biogenics Ltd.’s Net Margin is presently recorded at -3895.83.
Return on Equity for this stock declined to -72.01, with Return on Assets sitting at -56.26.
Vascular Biogenics Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.80 and a Current Ratio set at 2.80.
An analysis of insider ownership at Vascular Biogenics Ltd. [VBLT]
There are presently around $0 million, or 17.60% of VBLT stock, in the hands of institutional investors. The top three institutional holders of VBLT stocks are: MORGAN STANLEY with ownership of 429,611, which is approximately 13.68% of the company’s market cap and around 22.56% of the total institutional ownership; TELEMETRY INVESTMENTS, L.L.C., holding 403,500 shares of the stock with an approximate value of $68000.0 in VBLT stocks shares; and ACADIAN ASSET MANAGEMENT LLC, currently with $47000.0 in VBLT stock with ownership of nearly -51.034% of the company’s market capitalization.
9 institutional holders increased their position in Vascular Biogenics Ltd. [NASDAQ:VBLT] by around 132,575 shares. Additionally, 12 investors decreased positions by around 987,944 shares, while 9 investors held positions by with 1,370,146 shares. The mentioned changes placed institutional holdings at 2,490,665 shares, according to the latest SEC report filing. VBLT stock had 4 new institutional investments in for a total of 36,118 shares, while 2 institutional investors sold positions of 74,159 shares during the same period.